M&A season starts early? CSL seals $11.7B acquisition of Vifor Pharma
Australia’s CSL is plopping down $11.7 billion to acquire Vifor Pharma, the Swiss biotech best known for its iron products and kidney drugs.
While the buyout comes as little surprise — rumors have swirled since early December, and Vifor actually confirmed the deal talks to media on Monday — the final price could raise some eyebrows.
At $179.25 per share, CSL’s offer comes in much higher than the “more than $8.5 billion” price tag cited in reports.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.